Phathom Pharmaceuticals, Inc. Common Stock (PHAT)

Price$10.13

Value ScoreD

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-43.07%

Price vs S&P 500 (4W)-16.68%

VGM Score61.18

Market Capitalization$807.93M

All Metrics

Book Value / Share (Quarterly)$0.31

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.23

Price vs S&P 500 (YTD)-47.10%

Gross Margin (TTM)84.93%

Net Profit Margin (TTM)-76.77%

EPS (TTM)$-2.11

10-Day Avg Trading Volume1.37M

EPS Excl Extra (TTM)$-2.11

EPS (Annual)$-3.03

ROI (Annual)-88.87%

Gross Margin (Annual)87.09%

Cash / Share (Quarterly)$2.28

Revenue Growth QoQ (YoY)104.43%

ROA (Last FY)-85.37%

Revenue Growth TTM (YoY)150.30%

EBITD / Share (TTM)$-1.28

Operating Margin (TTM)-47.55%

Cash Flow / Share (Annual)$-2.34

P/B Ratio45.91x

P/B Ratio (Quarterly)44.50x

Net Income / Employee (Annual)$-596,400

EV / Revenue (TTM)5.72x

Net Interest Coverage (TTM)-2.62x

ROA (TTM)-59.65%

EPS Incl Extra (Annual)$-3.03

Current Ratio (Annual)1.73x

Quick Ratio (Quarterly)2.09x

3-Month Avg Trading Volume1.17M

52-Week Price Return115.99%

Revenue / Employee (TTM)$552,300

Tangible BV / Share (Quarterly)$-0.31

P/S Ratio (Annual)4.61x

Asset Turnover (Annual)0.68x

52-Week High$18.31

EPS Excl Extra (Annual)$-3.03

CapEx CAGR (5Y)-26.11%

26-Week Price Return-35.15%

Quick Ratio (Annual)1.58x

13-Week Price Return-5.68%

Total Debt / Equity (Annual)1.24x

Current Ratio (Quarterly)2.21x

Enterprise Value$1.17B

Asset Turnover (TTM)0.78x

Revenue / Employee (Annual)$472,000

Pretax Margin (Annual)-126.35%

Cash / Share (Annual)$1.82

3-Month Return Std Dev60.02%

Net Income / Employee (TTM)$-424,000

ROE (Last FY)-199.28%

Net Interest Coverage (Annual)-1.63x

EPS Basic Excl Extra (Annual)$-3.03

Receivables Turnover (TTM)3.50x

Total Debt / Equity (Quarterly)12.38x

EPS Incl Extra (TTM)$-2.11

ROI (TTM)-17.40%

P/S Ratio (TTM)3.94x

Revenue / Share (Annual)$2.40

Tangible BV / Share (Annual)$-1.80

Forward P/E150.57x

Price vs S&P 500 (52W)91.63%

Year-to-Date Return-38.94%

5-Day Price Return9.63%

EPS Normalized (Annual)$-3.03

ROA (5Y Avg)-83.68%

Net Profit Margin (Annual)-126.35%

Month-to-Date Return5.63%

Cash Flow / Share (TTM)$-3.74

EBITD / Share (Annual)$-2.19

Operating Margin (Annual)-91.36%

LT Debt / Equity (Annual)1.24x

LT Debt / Equity (Quarterly)12.36x

EPS Basic Excl Extra (TTM)$-2.11

P/B Ratio (Annual)8.32x

Inventory Turnover (TTM)6.38x

Pretax Margin (TTM)-76.77%

Book Value / Share (Annual)$2.36

Price vs S&P 500 (13W)-13.93%

Beta0.46x

Revenue / Share (TTM)$2.50

ROE (TTM)-232.78%

52-Week Low$4.47

vGradeD

gGradeA

mGradeC

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.37est. -0.33

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.18

4.24

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PHATPhathom Pharmaceuticals, Inc. Common Stock	D	A	C	$10.13
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its lead product, vonoprazan, is an oral potassium competitive acid blocker with demonstrated efficacy in treating gastroesophageal reflux disease and Helicobacter pylori infection. The compound exhibits rapid, potent, and durable acid-suppressive effects.